Flow Cytometry In Oncology And Immunology Market Report 2026

Flow Cytometry In Oncology And Immunology Market Overview

• Flow Cytometry In Oncology And Immunology market size has reached to $2.32 billion in 2025 • Expected to grow to $3.82 billion in 2030 at a compound annual growth rate (CAGR) of 10.5% • Growth Driver: Surge In HIV/AIDS Cases Is Anticipated To Fuel The Flow Cytometry Market Growth • Market Trend: Product Innovations With Spectral Flow Cytometry In Flow Cytometry • North America was the largest region in 2025.

What Is Covered Under Flow Cytometry In Oncology And Immunology Market?

Flow cytometry is a powerful analytical technique used in oncology and immunology to measure and analyze the physical and chemical characteristics of cells or particles as they flow in a fluid stream through a laser beam. This technology enables the simultaneous quantification of multiple cellular parameters, such as size, granularity, and the expression of surface and intracellular markers, facilitating the study of cell populations and their functions in health and disease. The main types of flow cytometry in oncology and immunology are immunology and oncology. Immunology is a branch of biomedical science that studies the immune system and its response to foreign substances known as antigens. In oncology and immunology, flow cytometry includes different technologies, such as cell-based flow cytometry and bead-based flow cytometry, used in several applications, including translational research and clinical research, by end users such as hospitals, diagnostic laboratories, reference laboratories, pharmaceutical and biotechnology companies, academic research institutes, contract research organizations, and others.

What Is The Flow Cytometry In Oncology And Immunology Market Growth Forecast?

The flow cytometry in oncology and immunology market size is expected to see rapid growth in the next few years. It will grow to $3.82 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to demand for personalized oncology diagnostics, integration with genomic data, growth in immuno-oncology therapies, expansion of clinical research pipelines, advances in multiplex analysis. Major trends in the forecast period include rising use in cancer biomarker identification, increased adoption in immune cell profiling, expansion of minimal residual disease detection, growing application in translational research, integration of high-dimensional data analysis.

What Is The Driver Of The Flow Cytometry In Oncology And Immunology Market?

The rising prevalence of HIV/AIDS is expected to propel the growth of flow cytometry in the oncology and immunology market going forward. HIV is a virus that attacks the body's immune system, specifically CD4 cells, white blood cells crucial for fighting infections. Over time, untreated HIV can lead to the disease AIDS, which is the final stage of HIV infection. Flow cytometry is a powerful technique used in HIV/AIDS research and clinical settings to analyze and characterize cells, particularly immune cells, based on their physical and chemical properties. Flow cytometry can be used to identify latently infected T cells harboring the HIV genome but not actively producing the virus. For instance, in July 2024, according to UNAIDS, a Switzerland-based UN program, in 2023, approximately 39.9 million people were living with HIV globally, up from 39.0 million in 2022. Therefore, the rising prevalence of HIV/AIDS is driving the flow cytometry in the oncology and immunology market.

Key Players In The Global Flow Cytometry In Oncology And Immunology Market

Major companies operating in the flow cytometry in oncology and immunology market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Becton Dickinson and Company, Agilent Technologies Inc., Sartorius AG, Beckman Coulter Inc., Bio-Rad Laboratories Inc., Sysmex Partec GmbH, Miltenyi Biotec, Luminex Corporation, Q2 Solutions LLC, BioLegend Inc., Cytek Biosciences Inc., Cell Signaling Technology Inc., Standard BioTools Inc., Sony Biotechnology Inc., NanoCellect Biomedical Inc., Nexcelom Bioscience LLC, CytoReason

Global Flow Cytometry In Oncology And Immunology Market Trends and Insights

Major companies operating in the flow cytometry in the oncology and immunology market are focusing on developing innovative solutions, such as spectral flow cytometry, to gain a competitive advantage. Spectral flow cytometry is a technology that captures the full emission spectrum of each fluorescent marker rather than detecting fixed, narrow-band signals, enabling much higher parameter, multiparametric cell analysis. For instance, in May 2024, Agilent Technologies, a US-based life science company, introduced the NovoCyte Opteon spectral flow cytometer, which supports three to five lasers, has up to 73 detectors, and enables analysis of more than 40 markers in a single run. This system enhances the capacity for deep immunophenotyping in oncology and immunology research. The advantages include flexibility in panel design, reduced spectral overlap, and improved signal resolution; however, it requires more complex data unmixing algorithms, potentially increasing analysis time.

What Are Latest Mergers And Acquisitions In The Flow Cytometry In Oncology And Immunology Market?

In February 2023, Cytek Biosciences, a U.S.-based provider of high-parameter flow cytometry instruments, reagents, software, and cell-analysis solutions, acquired Luminex Corporation’s Flow Cytometry & Imaging (FCI) business unit for an undisclosed amount. With this acquisition, Cytek aimed to expand its product portfolio to include imaging flow cytometry and menu-driven, application-specific cytometry, thereby offering a more comprehensive cell analysis platform. Luminex Corporation, a U.S.-based company, provides conventional and image-based flow cytometry instrumentation plus reagent products and services.

What Defines the Flow Cytometry In Oncology And Immunology Market?

The flow cytometry in oncology and immunology market includes revenues earned by entities by providing services such as cell-based assay services, drug development services, and minimal residual disease (MRD) monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The flow cytometry in oncology and immunology market also consists of sales of products flow cytometers, fluorescence-activated cell sorters (FACS), monoclonal antibodies, and fluorochromes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Flow Cytometry In Oncology And Immunology Market Report 2026?

The flow cytometry in oncology and immunology market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the flow cytometry in oncology and immunology industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.